Central hypothyroidism associated with retinoid X receptor-selective ligands

New England Journal of Medicine

Volumn 340, Issue 14, 1999, Pages 1075-1079

  Sherman, Steven I ^a   Gopal, Jayashree ^a   Haugen, Bryan R ^b   Chiu, Alice C ^a   Whaley, Kevin ^a   Nowlakha, Prem ^a   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; BEXAROTENE; LGD 346; LIGAND; LIOTHYRONINE; RETINOID X RECEPTOR; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; COLD SENSITIVITY; CONTROLLED STUDY; FATIGUE; FEMALE; GENETIC TRANSFECTION; HUMAN; HYPOTHYROIDISM; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROMOTER REGION; SKIN LYMPHOMA; T CELL LYMPHOMA; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROTROPIN RELEASE; THYROXINE BLOOD LEVEL;

AGED; COHORT STUDIES; HUMANS; HYPOTHYROIDISM; LIGANDS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; PROMOTER REGIONS (GENETICS); RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; TETRAHYDRONAPHTHALENES; THYROID FUNCTION TESTS; THYROID GLAND; THYROTROPIN; TRANSCRIPTION FACTORS;

EID: 0033535580     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199904083401404     Document Type: Article

References (22)

1. Breen JJ, Matsuura T, Ross AC, Gurr JA. Regulation of thyroid-stimulating hormone beta-subunit and growth hormone messenger ribonucleic acid levels in the rat: effect of vitamin A status. Endocrinology 1995;136: 543-9.
2. Haugen BR, Brown NS, Wood WM, Gordon DF, Ridgway EC. The thyrotrope-restricted isoform of the retinoid-X receptor-γl mediates 9-cis-retinoic acid suppression of thyrotropin-β promoter activity. Mol Endocrinol 1997;11:481-9.
3. Coya R, Carro E, Mallo F, Dieguez C. Retinoic acid inhibits in vino thyroid-stimulating hormone secretion. Life Sci 1997;60:247-50.
4. Boehm MF, Zhang L, Badea BA, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37:2930-41.
5. Lee HY, Dawson MI, Walsh GL, et al. Retinoic acid receptor-and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth Differ 1996;7:997-1004.
6. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996;56:5566-70.
7. Kizaki M, Dawson MI, Heyman R, et al. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood 1996;87:1977-84.
8. Fitzgerald P, Tcng M, Chandraratna RA, Heyman RA, Allegretto EA. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res 1997;57:2642-50.
9. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997;15:790-5.
10. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998;58:479-84.
11. Wood WM, Kao MY, Gordon DF, Ridgway EC. Thyroid hormone regulates the mouse thyrotropin beta-subunit promoter in transfected primary thyrotropes. J Biol Chem 1989;264:14840-7.
12. Haugen BR, Wood WM, Gordon DF, Ridgway EC. A thyrotrope-specific variant of Pit-1 transactivates the thyrotropin β promoter. J Biol Chem 1993;268:20818-24.
13. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997;7:891-6.
14. Abel EA, Wood GS, Hoppe RT. Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment. CA Cancer J Clin 1993;43:93-115.
15. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994;121:592-602.
16. Duvic MD, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;34:1022-9. [Erratum, J Am Acad Dermatol 1996;35:587.]
17. Heyman RA. A pharmacological dissection of RXR signaling pathways with rexinoids. In: Program & abstracts: 80th Annual Meeting of the Endocrine Society, New Orleans, June 24-27, 1998:22. abstract.
18. Mukherjee R, Strasser J, Jow L, Hoener P, Paterniti JR, Heyman RA. RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vase Biol 1998;18:272-6.
19. Mukherjee R, Davies PJ, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386:407-10.
20. Breen JJ, Hickok NJ, Gurr JA. The rat TSHbeta gene contains distinct response elements for regulation by retinoids and thyroid hormone. Mol Cell Endocrinol 1997;131:137-46.
21. Langlois MF, Bellarbarba D, Wondisford FE. RXR is an important cofactor in negative regulation of the TRH gene by thyroid hormone. Thyroid 1997;7:Suppl:S40. abstract.
22. Kakizawa T, Miyamoto T, Kaneko A, Yajima H, Ichikawa K, Hashizume K. Ligand-dependent heterodimerization of thyroid hormone receptor and retinoid X receptor. J Biol Chem 1997;272:23799-804.